合成 1,2,4-三唑并[5,1-][1,2,4]三嗪-7-酮的方法，作为抗病毒药物利阿莫尔（“Triazavirin®”）的基本杂环结构，对 SARS-CoV-2（COVID-19）有效。

Synthetic approaches to 1,2,4-triazolo[5,1-][1,2,4]triazin-7-ones as basic heterocyclic structures of the antiviral drug Riamilovir ("Triazavirin®") active against SARS-CoV-2 (COVID-19).

机构信息

I. Ya. Postovskiy Institute of Organic Synthesis, UB of the RAS, 22 S. Kovalevskoy Str., Yekaterinburg, 620219, Russian Federation.

Ural Federal University, 19 Mira str., Yekaterinburg, 620002, Russian Federation.

出版信息

Org Biomol Chem. 2022 Mar 2;20(9):1828-1837. doi: 10.1039/d1ob02125g.

DOI:10.1039/d1ob02125g

PMID:35137762

Abstract

Fragments of 1,2,4-triazolo[5,1-][1,2,4]triazin-7-one are found in many compounds with various types of biological activities, including the antiviral drug Riamilovir (Triazavirin®), which shows activity against SARS-CoV-2 (COVID-19). Therefore, the development of convenient methods for the synthesis of new derivatives of 1,2,4-triazolo[5,1-][1,2,4]triazin-7-one is always in demand. This review systematizes the information on the most common synthetic methods for constructing the 1,2,4-triazolo[5,1-][1,2,4]triazin-7-one heterocyclic system.

摘要

1,2,4-三唑并[5,1-α][1,2,4]三嗪-7-酮的片段存在于许多具有各种类型生物活性的化合物中，包括抗病毒药物利巴韦林（Triazavirin®），它对 SARS-CoV-2（COVID-19）具有活性。因此，开发合成 1,2,4-三唑并[5,1-α][1,2,4]三嗪-7-酮新衍生物的便捷方法一直是有需求的。本综述系统地总结了构建 1,2,4-三唑并[5,1-α][1,2,4]三嗪-7-酮杂环系统的最常见合成方法的信息。